A study recently published in The Annals of Thoracic Surgery, the official journal of the Society of Thoracic Surgeons and the Southern Thoracic Surgical Association, found that false-positive findings for CT-based screening for lung cancer were uncommon.
November is officially Lung Cancer Awareness Month. During the month, people throughout the country come together to support the lung cancer community and raise awareness about the disease.
Data from a new study recently published in the Journal of Thoracic Disease indicates that CyberKnife is a safe and effective treatment option for patients with lung metastases.
Whether it's you or a loved one facing a cancer diagnosis, making a treatment decision can be an overwhelming experience. While eradicating or controlling the disease is commonly a top consideration when choosing a treatment method, other factors such as maintaining quality of life during and after treatment may also be a concern for some patients.
The Journal of Clinical Oncology recently reported findings from a clinical trial that showed combining stereotactic body radiation therapy (SBRT) with chemotherapy improved survival rates among 24 stage IV lung cancer patients.
The American College of Radiology (ACR) has certified Reno CyberKnife’s hospital partner, Saint Mary’s Center for Cancer, as a designated Lung Cancer Screening Center.
A cancer diagnosis affects not only the person battling the disease, but also their friends and family. Providing support for a loved one or taking on the role of a caregiver for someone diagnosed with cancer can be an emotional and challenging time.
The top consideration and question many patients have when assessing their treatment options is ‘how effective is the treatment?’. Patients should research the treatment options presented to them to understand what clinical studies say about the treatment and how the treatment can best fit into their current lifestyle.
A recent analysis from a multidisciplinary team of scientists affiliated with the University of Pittsburgh Cancer Institute provides rationale for a national clinical trial to assess the effectiveness of adding head and neck cancer screening to lung cancer screening programs.